

Delays in early reperfusion for ST-segment-elevation myocardial infarction An Observational multi-centre study in South African hospitals



**Dear Patient** 

PATIENT COPY

We invite you to participate in a research study. This information leaflet will help you to decide whether you would like to participate. Before you agree to take part you should fully understand what participation entails. If you have any questions that this leaflet does not fully explain, please do not hesitate to ask your cardiologist.

### THE NATURE AND PURPOSE OF THIS STUDY

The aim of this study is to determine which factors lead to a delay in treatment of a heart attack in Tshwane hospitals. Your history as a patient is a very important source of information on how these delays may be prevented so that in future treatment can commence as soon as possible in patients with heart attacks.

### EXPLANATION OF PROCEDURES TO BE FOLLOWED

This study involves the recoding of relevant information of your case by the cardiologist that is treating you. We will ask you some questions about your medical status preceding the heart attack, details of your symptoms, and how you got to hospital. Your diagnosis and treatment will be recorded until you are discharge from the hospital.

#### RISK AND DISCOMFORT INVOLVED

There are no risks in participating in the study. The interview will take about 15 minutes of your time.

#### POSSIBLE BENEFITS OF THIS STUDY

Although you will not benefit directly from the study, the results of the study will enable us to improve the care of patients with heart attacks in future.

#### WHAT ARE YOUR RIGHTS AS A PARTICIPANT?

Your participation in this study is entirely voluntary. You can refuse to participate or stop at any time during your treatment without giving any reason. Your withdrawal will not affect you or your treatment in any way.

#### HAS THE STUDY RECEIVED ETHICAL APPROVAL?

This study has received written approval from the Research Ethics Committee of the Faculty of Health Sciences at the University of Pretoria, telephone numbers 012 3541677 / 012 3541330

#### INFORMATION AND CONTACT PERSON

The contact persons for the study are Prof Rhena Delport and Dr Adriaan Snyders. If you have any questions about the study please contact them at the following telephone numbers: 082 445 4500 or 082 446 1558.

#### COMPENSATION

Your participation is voluntary. No compensation will be given for your participation.

#### CONFIDENTIALITY

All information that you give will be kept strictly confidential. Once we have analysed the information no one will be able to identify you as participant. Research reports and articles in scientific journals will not include any information that may identify you, your cardiologist, or the hospitals where you were treated.



Delays in early reperfusion for ST-segment-elevation myocardial infarction An Observational multi-centre study in South African hospitals



## CONSENT TO PARTICIPATE IN THIS STUDY

PATIENT COPY

I confirm that the person asking my consent to take part in this study has told me about nature, process, risks, discomforts and benefits of the study. I have also received, read and understood the above written information (Information Leaflet and Informed Consent) regarding the study. I am aware that the results of the study, including personal details, will be anonymously processed into research reports. I am participating willingly. I have had time to ask questions and have no objection to participate in the study. I understand that there is no penalty should I wish to discontinue with the study and my withdrawal will not affect any treatment in any way.

I have received a signed copy of this informed consent agreement.

	Name (Print)	Signature	Date
Participant			
Investigator			
Witness			

# VERBAL INFORMED CONSENT

I, the undersigned, have read and have fully explained the participant information leaflet, which explains the nature, process, risks, discomforts and benefits of the study to the participant whom I have asked to participate in the study.

The participant indicates that s/he understands that the results of the study, including personal details regarding the interview will be anonymously processed into a research report. The participant indicates that s/he has had time to ask questions and has no objection to participate in the interview. S/he understands that there is no penalty should s/he wish to discontinue with the study and his/her withdrawal will not affect any treatment in any way. I hereby certify that the client has agreed to participate in this study.

	Name (Print)	Signature	Date
Participant			
Person seeking consent			
Witness			



Delays in early reperfusion for ST-segment-elevation myocardial infarction An Observational multi-centre study in South African hospitals



## CONSENT TO PARTICIPATE IN THIS STUDY

STUDY COPY

I confirm that the person asking my consent to take part in this study has told me about nature, process, risks, discomforts and benefits of the study. I have also received, read and understood the above written information (Information Leaflet and Informed Consent) regarding the study. I am aware that the results of the study, including personal details, will be anonymously processed into research reports. I am participating willingly. I have had time to ask questions and have no objection to participate in the study. I understand that there is no penalty should I wish to discontinue with the study and my withdrawal will not affect any treatment in any way.

I have received a signed copy of this informed consent agreement.

	Name (Print)	Signature	Date
Participant			
Investigator			
Witness			

# VERBAL INFORMED CONSENT

I, the undersigned, have read and have fully explained the participant information leaflet, which explains the nature, process, risks, discomforts and benefits of the study to the participant whom I have asked to participate in the study.

The participant indicates that s/he understands that the results of the study, including personal details regarding the interview will be anonymously processed into a research report. The participant indicates that s/he has had time to ask questions and has no objection to participate in the interview. S/he understands that there is no penalty should s/he wish to discontinue with the study and his/her withdrawal will not affect any treatment in any way. I hereby certify that the client has agreed to participate in this study.

	Name (Print)	Signature	Date
Participant			
Person seeking consent			
Witness			



Delays in early reperfusion for ST-segment-elevation myocardial infarction An Observational multi-centre study in South African hospitals



Sticker

## SA HEART SASCI STEMI EARLY REPERFUSION PROJECT

Today's date	
Hospital	
Patient Name	
Patient number	
Contact number	
Cardiologist	

## CLINICAL EXAMINATION AND HISTORY

Sex		∖ge	e Height		Weight		Waist Circ	umference	Hear	t Rate
O Male O Fem	ale	yrs		cm		kg		cm		/min
O Smoking	years	Amount pe	er Day	O Ex-Smoker		Amount per Day	, C	) Never S	moked	
Physical activity	O Less tha	n modera	te O	Moderat	e (30min	3-5 time	s per week)	O Mor	e than mo	derate

#### THROMBOLYSIS

Medication prior to Thrombolysis	Dosage	Date	Time	Thrombolytic agent			
Asprin				Select Any	Streptokinase	Tenecteplase	Reteplase
Clopidogrel				Dosage			
Unfractionated Heparin						Date	Time
Ticagrelor				Start Date &	& Time		
Other				End Date &	Time		
Other				90-120 min	ECG		
Other				Successful	Lysis		



Delays in early reperfusion for ST-segment-elevation myocardial infarction An Observational multi-centre study in South African hospitals



## CARDIAC HISTORY(If coronaropathy known before the MI)

Previous MI (1)	Date & localization
Previous MI (2)	Date & localization
Stable AP	Duration (Years / mo) & detail
CABG	Date & detail
PCI (1)	Date & detail
PCI (2)	Date & detail
Other	Date & detail

		DIA	GNOSIS		
ECG 1 Date & time		ECG 2 Date & ti	me	Diagnosis Confir Date and time	rmed
Chest discomfort / Loo	cation of Pain				
Pain Severity (1-10)		Palpitation	Pallor	Diaphoresis	Shortness of breath
		Nausea/ vomiting	Dizziness	Syncope	

COMORBID CONDITIONS						
Previous IHD	Duration (Years / mo) & detail	Duration (Years / mo) & detail				
Family history of premature CVD 1st degree relative <55 years in men or <65 in women	Detail	Unknown				
Hypertension	Duration if yes: years/months					
Diabetes type 2	Duration if yes: years/months	Most recent HbA1C (%) Fasting glucose (mmol/L)	Date reported			
Diabetes type 1	Duration if yes: years/months	Most recent HbA1C (%) Fasting glucose (mmol/L)	Date reported			
Hypercholesterolemia Treated hypercholesterolemia or Total LDL chol. > 2,5mmol/L	Duration if yes: years/months	Total chol (mmol/L ) LDL chol (mmol/L) HDL chol (mmol/L) Triglycerides mmol/L	Date reported			



Delays in early reperfusion for ST-segment-elevation myocardial infarction An Observational multi-centre study in South African hospitals



PATIENT JOURNEY									
Event			Comment		[	Date	Tim	e	Unknown
Symptom onset									
First medical contact (FMC)					[	Date	Tim	e	Unknown
Paramedic	[	ER at non-	-PCI-capable						
GP consulting room	[	ER at PC	l-capable hospital						_
Cardiologist consulting room		Other							
Strategy with FMC									
Immediate transfer for p-PC	[	Secondary	r transfer						
Fibrinolysis and immediate to	ransfer [	🗌 No reperfu	ision in acute stage						
Transport intervals (hours/mi	,								
EMS call to response time E	MS arrival to de	eparture time	EMS transport to	o hospital tir	ne	Personal tra	anspor	t to ho	spital time
Total distance travellad to be									
Total distance travelled to ho Referral pathway	spital (km)					Date	ті	me	Unknown
Arrival at non-PCI-capab	le hospital					Date		me	
Departure from non-PCI-		ital							
Arrival at PCI-capable he									
Admission to		🗌 ER							
		Cathlab							
		Other							
Arrival in Cathlab		_							
Angioplasty						Date		Time	•
Primary PCI									
Coronary angiography with for the onset of symptoms	ollow-on PCI i	in patients p	resenting within >	12 hours c	of				
Coronary angiography with for of fibrinolytics in patients with			n 60–90 min after	administra	ation				
Coronary angiography with follow-on rescue PCI in patients with recurrent myocardial ischemia after fibrinolysis									
froutinone of guilty	f DES used -eluting stents		. of BMS used are metal stents)	No		alloons		of G\ ide wi	Ws used ires)
Thrombectomy Aspirat	ion 🗌 E	Balloon only	Simultaneou	us treatmen	t of oth	er lesions			
Thrombolysis intra coronary Complete revascularisation									
Comments:									



Delays in early reperfusion for ST-segment-elevation myocardial infarction An Observational multi-centre study in South African hospitals



Post-PCI	Date	Time	Comment
Transfer to ICU			
Transfer to ward			
Transfer to rehabilitation facility			
Transfer to referral hospital			
Discharge from hospital			
Non: Deceased			
Adult smoking advice or counselling given			
Pre-discharge patient education provided			

### DISCHARGE MEDICATION

MEDICATION	Dosage	MEDICATION	Dosage

### Comments

Please feel free to add any comments that you feel may be of use in understanding the data collected. Include information on adverse events, e.g. cardiac arrest ....

Questionnaire completed by	Contact details



Delays in early reperfusion for ST-segment-elevation myocardial infarction An Observational multi-centre study in South African hospitals



	SA HEART SASCI STEMI EARLY REPERFUSION PROJECT – FOLLOW-UP			
Today's date	Stic	ker		
Hospital				
Patient Name				
Patient number				
Contact number	r			
Cardiologist				
Follow-up report on first visit				
Date:				
	Follow-up report on next visit			
Date:				
	12 Months outcome			
Report completed	d by Contact details			